

knkdns

Protocol Number: dsdcsd

NCT Number: jbdcbs

Principal Investigator: ckdckd

Sponsor: kjnsdkc

Funded By: djsdsdc

Version: v1.0

Date: 2025-12-16

TABLE OF CONTENTS

- STATEMENT OF COMPLIANCE
- 1 PROTOCOL SUMMARY
- 2 INTRODUCTION
- 3 OBJECTIVES AND ENDPOINTS
- 4 STUDY DESIGN
- 5 STUDY POPULATION
- 6 STUDY INTERVENTION
- 7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL
- 8 STUDY ASSESSMENTS AND PROCEDURES
- 9 STATISTICAL CONSIDERATIONS
- 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
- 11 REFERENCES
- APPENDICES

STATEMENT OF COMPLIANCE

The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical Practice (ICH GCP) and the following:

- United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)
- National Institutes of Health (NIH)-funded investigators and clinical trial site staff who are responsible for the conduct, management, or oversight of NIH-funded clinical trials have completed Human Subjects Protection and ICH GCP Training.
- The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board (IRB) for review and approval.

1 PROTOCOL SUMMARY

1.3 Schedule of Activities (SoA)

3 OBJECTIVES AND ENDPOINTS



Figure: nexus

ghvfddhvbegvbdywgweufchweojcvqbevdnv dwebvhwqbyvuetewcwe dvbrevbwwegcweyfgcweuhf

Type	dc dc vdc v	Endpoints	fdjivedhv
jhcxsuhvcxgs	dchusdgvyygvyd	dcdv	dcysdgcywegcyeg
deygdyegwfyegf	efvewgbeyyef	geyfre	hfuhewf
ewgfywefgweywey	hgcuifwgfywe	ufweuf	wefgefefuew
gfeugewyfbewf	yefbewgew	yfgewfyge	hwebfwefyf gew

